Literature DB >> 3940664

Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique.

P L Ludmer, R F Wright, J M Arnold, P Ganz, E Braunwald, W S Colucci.   

Abstract

To determine the relative contributions of milrinone's positive inotropic and vasodilator actions in patients with severe congestive heart failure, the drug was administered by constant infusion directly into the left main coronary artery of 11 patients with New York Heart Association functional class III or IV heart failure. Intracoronary infusion of milrinone at rates up to 50 micrograms/min had no effect on mean arterial pressure or systemic vascular resistance but resulted in dose-related increases in peak positive dP/dt (+21%), stroke volume index (+18%), and stroke work index (+21%) and decreases in heart rate (-3%), mean right atrial pressure (-25%), and left ventricular end-diastolic pressure (-17%). In eight patients, intravenous administration (75 micrograms/kg) after the intracoronary infusion resulted in significant decreases in mean arterial pressure (-14%) and systemic vascular resistance (-40%), further increase in stroke volume index compared with intracoronary administration, and further decreases in mean right atrial and left ventricular end-diastolic pressures compared with intracoronary administration. These data indicate that milrinone exerts both positive inotropic and vasodilator actions that contribute significantly to the drug's overall hemodynamic effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940664     DOI: 10.1161/01.cir.73.1.130

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: differentiation between aorta and common carotid artery.

Authors:  M Seki; K Mizushige; T Ueda; M Kitadai; H Matsuo
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs.

Authors:  A Dorszewski; B Müller-Beckmann; L Kling; G Sponer
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

Review 3.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 4.  Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.

Authors:  S F Shakar; M R Bristow
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 5.  Congestive heart failure. New frontiers.

Authors:  W W Parmley; K Chatterjee; G S Francis; B G Firth; R A Kloner
Journal:  West J Med       Date:  1991-04

Review 6.  Inotropic agents for heart failure: what if digoxin increases mortality?

Authors:  W J Remme
Journal:  Br Heart J       Date:  1994-09

7.  Unmasking of neonatal renovascular hypertension by milrinone used for cardiac dysfunction.

Authors:  Prema Ramaswamy; Susan Schulman; Panayot Filipov; Juan C Kupferman
Journal:  Pediatr Cardiol       Date:  2011-06-09       Impact factor: 1.655

8.  Effects of commonly used inotropes on myocardial function and oxygen consumption under constant ventricular loading conditions.

Authors:  Elizabeth S DeWitt; Katherine J Black; Ravi R Thiagarajan; James A DiNardo; Steven D Colan; Francis X McGowan; John N Kheir
Journal:  J Appl Physiol (1985)       Date:  2016-05-05

9.  The positive inotropic response to milrinone in isolated human and guinea pig myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-10       Impact factor: 3.000

10.  Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases.

Authors:  R R Reinhardt; E Chin; J Zhou; M Taira; T Murata; V C Manganiello; C A Bondy
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.